T1	Participants 66 85	GH-deficient adults
T2	Participants 365 509	Sixty-eight patients (44 men and 24 women) with a mean age of 44.3 (1.2) yr and verified GH deficiency participated in a 2-phase treatment trial
T3	Participants 647 682	patients 12 months of GH treatment.
